Clinical trials: JAK2 Mutation
Polycythemia Vera (PV), Myelofibrosis (MF)
Study of ZE74-0282 for Patients With JAK2 V617F Positive Blood Cancers
This study will test an experimental drug called ZE74-0282 in people with certain blood disorders caused by a specific mutation called JAK2 V617F.
- Trial name
- NCT07529951
- Testing
- ZE74-0282
- Volunteers
- 60 people
- Sponsor
- Eilean Therapeutics
Essential Thrombocythaemia
A Study to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythaemia Patients
The primary objective of this study is to assess the efficacy of ropeginterferon alfa-2b in patients with ET who need cytoreductive treatment but are intolerant or refractory to, and/or ineligible for cytoreductive treatments…
- Trial name
- NCT06514807
- Testing
- Ropeginterferon alfa-2b (BESREMi®)
- Where
- 36 sites in Austria, Czechia and 8 more
- Volunteers
- 117 people
- Sponsor
- AOP Orphan Pharmaceuticals AG
Polycythemia Vera, Essential Thrombocytosis
Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis
This is an 18-week open-label, multicenter study to evaluate the efficacy and tolerability of CEP-701 (lestaurtinib) treatment in patients with Polycythemia Vera (PV) and patients with Essential Thrombocytosis (ET).
- Trial name
- NCT00586651
- Testing
- lestaurtinib
- Where
- 4 sites in United States
- Volunteers
- 39 people
- Sponsor
- Cephalon
Essential Thrombocythemia (ET)
Exploratory Multi-centre Trial In Patients With ET Treated With XAGRID®
This study is hypothesis-generating to explore the impact of JAK2 (V617F) mutation status on the treatment response to anagrelide hydrochloride
- Trial name
- EMIX (NCT01352585)
- Testing
- Anagrelide hydrochloride
- Where
- 10 sites in Italy
- Volunteers
- 47 people
- Sponsor
- Shire
Myelofibrosis, Myelofibrosis Due to and Following Polycythemia Vera
Flonoltinib Maleate Oral Regimens in Patients With Myelofibrosis
The goal of this clinical trial is to learn which of three different doses of Flonoltinib Maleate taken by mouth daily works best to treat adult patients with myelofibrosis in whom the most common approved therapy has failed to…
- Conditions
- Myelofibrosis, Myelofibrosis Due to and Following Polycythemia Vera, Myelofibrosis Transformation in Essential Thrombocythemia, Myelofibrosis With High Molecular Risk Mutations
- Trial name
- FM-MF-02 (NCT07750574)
- Testing
- Flonoltinib Maleate orally
- Volunteers
- 105 people
- Sponsor
- Chengdu Zenitar Biomedical Technology Co., Ltd
Myelofibrosis
A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy
The study is a designed to evaluate safety and activity of APG-1252 when administered as monotherapy and in combination with ruxolitinib in previously ruxolitinib treated myelofibrosis patients.
- Trial name
- NCT04354727
- Testing
- APG-1252, Ruxolitinib
- Where
- 2 sites in United States
- Sponsor
- Ascentage Pharma Group Inc.